IGC Pharma, Inc.IGCNYSE
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank49
5Y CAGR-42.2%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-42.2%/yr
Long-term compound
Percentile
P49
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 3.05% |
| Q3 2025 | 16.72% |
| Q2 2025 | 112.30% |
| Q1 2025 | -49.65% |
| Q4 2024 | 8.55% |
| Q3 2024 | -37.66% |
| Q2 2024 | 24.63% |
| Q1 2024 | -35.82% |
| Q4 2023 | 49.46% |
| Q3 2023 | -7.48% |
| Q2 2023 | -58.16% |
| Q1 2023 | 154.87% |
| Q4 2022 | -23.67% |
| Q3 2022 | 32.69% |
| Q2 2022 | -73.80% |
| Q1 2022 | 157.78% |
| Q4 2021 | -49.64% |
| Q3 2021 | 131.42% |
| Q2 2021 | -28.50% |
| Q1 2021 | 13.63% |
| Q4 2020 | 47.40% |
| Q3 2020 | -15.50% |
| Q2 2020 | -20.66% |
| Q1 2020 | 56.55% |
| Q4 2019 | 29.16% |
| Q3 2019 | -12.41% |
| Q2 2019 | -20.14% |
| Q1 2019 | 93.80% |
| Q4 2018 | -7.56% |
| Q3 2018 | 57.68% |
| Q2 2018 | -15.24% |
| Q1 2018 | 28.75% |
| Q4 2017 | 53.20% |
| Q3 2017 | -24.11% |
| Q2 2017 | -52.33% |
| Q1 2017 | 183.39% |
| Q4 2016 | -4.88% |
| Q3 2016 | 10.34% |
| Q2 2016 | -78.54% |
| Q1 2016 | 227.61% |